Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
upadacitinib (ABT-494)
Biotech
AbbVie’s JAK1 upadacitinib hits arthritis, but death registered in test
AbbVie has scored another key trial win with its JAK1 inhibitor upadacitinib, but a death and pulmonary embolism take some of the shine off the data.
Ben Adams
Dec 20, 2017 8:50am
AbbVie preps JAK atopic dermatitis candidate for phase 3
Sep 8, 2017 10:49am